Cancer Immunology, Immunotherapy

, Volume 65, Issue 9, pp 1135–1147

Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes

  • Kristoffer Sand
  • Jakob Theorell
  • Øystein Bruserud
  • Yenan T. Bryceson
  • Astrid Olsnes Kittang
Original Article

DOI: 10.1007/s00262-016-1865-y

Cite this article as:
Sand, K., Theorell, J., Bruserud, Ø. et al. Cancer Immunol Immunother (2016) 65: 1135. doi:10.1007/s00262-016-1865-y



Myelodysplastic syndromes (MDS) are a group of clonal bone marrow disorders, with dysplasia, cytopenias and increased risk of progression to acute myeloid leukemia. A dysregulated immune system precipitates MDS, and to gain insights into the relevance of cytotoxic T lymphocyte (CTL) in this process, we examined the frequency and function of CX3CR1- and CD57-positive T lymphocytes from MDS patients.

Materials and methods

Peripheral blood and/or bone marrow samples from 31 MDS patients and 12 healthy controls were examined by flow cytometry. Expression of cytotoxic granule constituents, immunological co-receptors, adhesion molecules and markers of activation were quantified on unstimulated lymphocytes. Degranulation, cytotoxicity and conjugate formation with target cells following co-culture of CTL with target cell lines or autologous bone marrow-derived CD34+ cells were quantified by flow cytometry.


CX3CR1 expression was increased in bone marrow from high-risk MDS patients compared to healthy controls. Expression of CD57 and CX3CR1 was closely correlated, identifying a CTL subset with high cytotoxic capacity. In vitro, TCR-induced redirected cytotoxicity was markedly decreased for high-risk MDS patients compared to controls. CTL from MDS patients with the lowest target cell cytotoxicity had reduced expression of adhesion molecules and formed fewer conjugates with target cells.


Although phenotypically defined CTL numbers were increased in the bone marrow of MDS patients, we found that CTL from high-risk MDS patients exhibited a lower TCR-induced redirected cytotoxic capacity. Thus, decreased T cell cytotoxicity seems related to reduced adhesion to target cells and may contribute to impaired anti-leukemic immune surveillance in MDS.


Myelodysplastic syndromes Cytotoxic T lymphocytes CD57 CX3CR1 Granzyme B Adhesion 



Acute myeloid leukemia


Bone marrow mononuclear cell


Cytotoxic T lymphocyte


International prognostic scoring system revised


Kruskal–Wallis test


Mann–Whitney U test


Myelodysplastic syndromes


PanToxiLux substrate


Refractory anemia with excess of blasts


Refractory anemia with ring sideroblasts


Refractory anemia with multilineage dysplasia


T regulatory cell

Supplementary material

262_2016_1865_MOESM1_ESM.pdf (97 kb)
Supplementary material 1 (PDF 96 kb)

Funding information

Funder NameGrant NumberFunding Note
Helse Vest (NO)
    Kreftforeningen (NO)
      Universitetet i Bergen (NO)

        Copyright information

        © Springer-Verlag Berlin Heidelberg 2016

        Authors and Affiliations

        1. 1.Department of Clinical ScienceUniversity of BergenBergenNorway
        2. 2.Center for Infectious Medicine, Department of Medicine, Karolinska InstitutetKarolinska University Hospital HuddingeStockholmSweden
        3. 3.Division for Hematology, Department of MedicineHaukeland University HospitalBergenNorway

        Personalised recommendations